Daniel Lyons, Ph.D., CFA
Daniel Lyons is a Portfolio Manager on the Health Care and Biotech Teams at Janus Henderson Investors, a role he has held since 2018. He is also a Research Analyst on the Healthcare team since 2000 and focuses on biotechnology and life science tools sectors. Daniel started consulting for Janus in 1997 and joined the research team full time in 2000.
Daniel received his Bachelor of Arts degree in biochemistry and chemistry from Rice University, graduating magna cum laude. He also earned a PhD from Stanford University’s programme in immunology and conducted postdoctoral research with a Nobel Laureate at the University of Colorado. He holds the Chartered Financial Analyst designation and has 25 years of financial industry experience.
Articles Written
A gameplan for healthcare investing amid policy uncertainty
These company characteristics could help investors win out over looming tariffs and federal funding cuts in the healthcare sector.
Global Perspectives: What’s next for booming weight-loss drugs
New GLP-1 weight-loss drugs have already hit $50 billion in annual sales – and look to have plenty of room to grow.
JH Explorer: Takeaways from the 2025 J.P. Morgan Healthcare Conference
After attending the sector’s preeminent annual gathering, we are as confident as ever in healthcare’s long-term value.
Trailing the S&P 500, healthcare stocks look deeply undervalued
We think the market has gone too far in discounting near-term headwinds for the sector, creating an opportunity for investors.
Despite political headwinds, healthcare stocks stay anchored to innovation
Andy Acker and Dan Lyons say healthcare investors should expect volatility in 2025 – but also plenty of opportunities for long-term growth.
Healthcare stocks shine in a dimming economy
The sector’s traditionally defensive qualities and accelerating innovation could stand out amid a potentially slowing economy.
Will a new candidate create volatility for healthcare stocks?
Why we do not expect the last-minute change in the U.S. presidential election to lead to heightened volatility in healthcare stocks.
Biotech sector update: Going for gold
Amid interest rate cuts and accelerating innovation, the biotechnology sector could be set up for strong performance.